Tocilizumab: Difference between revisions
From IDWiki
(→) |
No edit summary |
||
| Line 10: | Line 10: | ||
**Weight >65 and ≤90 kg: 600 mg |
**Weight >65 and ≤90 kg: 600 mg |
||
**Weight >90 kg: 800 mg |
**Weight >90 kg: 800 mg |
||
| + | |||
| + | == Safety == |
||
| + | |||
| + | === Infections === |
||
| + | |||
| + | * Compared to [[TNF-α inhibitors]], has a higher risk of serious bacterial infection, [[skin and soft tissue infection]], and [[diverticulitis]][[CiteRef::pawar2019ri]] |
||
| + | * There does not appear to be an increased risk of non-bacterial infections[[CiteRef::lang2011ri]] |
||
[[Category:Medications]] |
[[Category:Medications]] |
||
Revision as of 14:50, 25 February 2021
Background
- IL-6 antagonist
Dosing
- SARS-CoV-2 with acutely declining patients, as a single dose infused over 60 minutes
- Weight ≤40 kg: 8 mg/kg
- Weight >40 and ≤65 kg: 400 mg
- Weight >65 and ≤90 kg: 600 mg
- Weight >90 kg: 800 mg
Safety
Infections
- Compared to TNF-α inhibitors, has a higher risk of serious bacterial infection, skin and soft tissue infection, and diverticulitis1
- There does not appear to be an increased risk of non-bacterial infections2
References
- ^ Ajinkya Pawar, Rishi J Desai, Daniel H Solomon, Adrian J Santiago Ortiz, Sara Gale, Min Bao, Khaled Sarsour, Sebastian Schneeweiss, Seoyoung C Kim. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study. Annals of the Rheumatic Diseases. 2019;78(4):456-464. doi:10.1136/annrheumdis-2018-214367.
- ^ Veronika R. Lang, Matthias Englbrecht, Jürgen Rech, Hubert Nüsslein, Karin Manger, Florian Schuch, Hans-Peter Tony, Martin Fleck, Bernhard Manger, Georg Schett, Jochen Zwerina. Risk of infections in rheumatoid arthritis patients treated with tocilizumab. Rheumatology. 2011;51(5):852-857. doi:10.1093/rheumatology/ker223.
